<DOC>
	<DOC>NCT02950298</DOC>
	<brief_summary>The primary purpose of this study is to: - Document the developmental outcomes of individuals with Pompe disease treated with long-term enzyme-replacement therapy (ERT) through school-age (ages 6-18) using measures of cognitive functioning, academic skills, and speech and language abilities. - Investigate possible cognitive processing speed weaknesses using BrainBaseline neurocognitive assessment software. - Investigate the relationship between behavior and other developmental factors including speech and language ability and cognitive ability. - Explore if the use of selected iPad applications may help strengthen cognitive processing speed in children with Pompe disease</brief_summary>
	<brief_title>Pompe Telemedicine Developmental Study</brief_title>
	<detailed_description>The study will last approximately 2-3 years. It includes 2-4 visits to Duke for developmental assessments. The baseline/year 1 visit may take place at Duke (may take 1-2 days) or remotely via iPad. The follow up 1/year 2 visit may take place at Duke (1-2 days) or remotely via an iPad, depending upon each child's particular situation.</detailed_description>
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Glycogen Storage Disease</mesh_term>
	<criteria>Age range 618 years Diagnosis of classic Pompe disease by enzyme or molecular methods Patient, parent, or legal guardian is willing and able to give written informed consent English speaking child and care giver.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pompe</keyword>
	<keyword>Glycogen Storage Disease II</keyword>
	<keyword>Telemedicine</keyword>
	<keyword>Duke University Medical Center</keyword>
</DOC>